AstraZeneca's experimental COPD drug cuts flare-ups by roughly one-third in late-stage trials
Phase 3 studies show AstraZeneca's inhaled antibody tozorakimab reduced COPD exacerbations by about 30% over a year, offering a potential new therapy for the disease.
AstraZeneca reported that its experimental COPD treatment, tozorakimab, achieved a 30% reduction in disease exacerbations in two Phase 3 trials spanning a year. The findings were unveiled at the European Respiratory Society's annual conference in Barcelona and later appeared in the New England Journal of Medicine. Unlike recent COPD medicines, the tozorakimab studies included patients who could not receive those newer therapies, potentially opening a sizable market segment.
The drug, referred to as “tozo,” is administered by injection and is also being evaluated for asthma. Industry analysts project that, pending regulatory approval, the product could generate billions of dollars in annual sales, marking a major commercial win for AstraZeneca after recent setbacks with other cardiovascular candidates.
Why it matters
A new COPD therapy could improve outcomes for millions and boost AstraZeneca's revenue stream.
In this story
